HIGHLIGHTS
- who: Report et al. from the Internal and Hospital Medicine, Moffitt Cancer Center, Tampa, USA Pharmacy, Moffitt Cancer Center, Tampa, USA have published the research work: Review began 01/26/2023 Review ended 03/04/2023 Published 03/05/2023 u00a9 Copyright, in the Journal: (JOURNAL) of March/05,/2023
- what: DKA due to brentuximab treatment for HL is a rare condition.
- future: Studies are needed to elucidate specific patient risk factors that may increase susceptibility to rare inflammatory or immune-related events from targeted immunotherapies.
SUMMARY
Some rare . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.